Cargando…

A Perspective of Immunotherapy for Prostate Cancer

In cancer patients, the immune system is often altered with an excess of inhibitory factors, such as immunosuppressive cytokines, produced by regulatory T cells (Treg) or myeloid-derived suppressor cells (MDSC). The manipulation of the immune system has emerged as one of new promising therapies for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Silvestri, Ida, Cattarino, Susanna, Giantulli, Sabrina, Nazzari, Cristina, Collalti, Giulia, Sciarra, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963806/ https://www.ncbi.nlm.nih.gov/pubmed/27399780 http://dx.doi.org/10.3390/cancers8070064

Ejemplares similares

Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer
por: Silvestri, Ida, et al.
Publicado: (2015)

AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways
por: Tortorella, Elisabetta, et al.
Publicado: (2023)

Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review
por: Sciarra, Alessandro, et al.
Publicado: (2016)

Effect of Serenoa repens (Permixon®) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinoma
por: Silvestri, Ida, et al.
Publicado: (2013)

Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: A critical review
por: Sciarra, Alessandro, et al.
Publicado: (2019)

Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients?
por: Sciarra, Alessandro, et al.
Publicado: (2023)

[Retracted] Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells
por: Taglieri, Ludovica, et al.
Publicado: (2023)

Exosome Analysis in Prostate Cancer: How They Can Improve Biomarkers’ Performance
por: Salciccia, Stefano, et al.
Publicado: (2023)

How the Analysis of the Pathogenetic Variants of DDR Genes Will Change the Management of Prostate Cancer Patients
por: Sciarra, Alessandro, et al.
Publicado: (2022)

A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer
por: Sciarra, Alessandro, et al.
Publicado: (2016)

Prognostic Value of Albumin to Globulin Ratio in Non-Metastatic and Metastatic Prostate Cancer Patients: A Meta-Analysis and Systematic Review
por: Salciccia, Stefano, et al.
Publicado: (2022)

Laparoscopic versus open radical prostatectomy in high prostate volume cases: impact on oncological and functional results
por: Alessandro, Sciarra, et al.
Publicado: (2016)

Effect of 1-MHz ultrasound on the proinflammatory interleukin-6 secretion in human keratinocytes
por: Giantulli, Sabrina, et al.
Publicado: (2021)

Perspectives on the clinical development of immunotherapy in prostate cancer
por: Cordes, Lisa M, et al.
Publicado: (2018)

Immunotherapy in prostate cancer: current state and future perspectives
por: Handa, Shivani, et al.
Publicado: (2020)

Immunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives
por: Maselli, Felicia Maria, et al.
Publicado: (2023)

Is There a Role for Immunotherapy in Prostate Cancer?
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Immunotherapy in Prostate Cancer
por: Fay, Emily K., et al.
Publicado: (2020)

Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review
por: Kim, Tae Jin, et al.
Publicado: (2020)

Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
por: Bansal, Dhruv, et al.
Publicado: (2021)

Immunotherapy in metastatic prostate cancer
por: Slovin, Susan F.
Publicado: (2016)

Hepatitis B vaccination and immunotherapies: an update
por: Stasi, Cristina, et al.
Publicado: (2020)

Which factors can influence post-operative renal function preservation after nephron-sparing surgery for kidney cancer: a critical review
por: Di Lascio, Giovanni, et al.
Publicado: (2022)

Sipuleucel-T: immunotherapy for advanced prostate cancer
por: Olson, Brian M, et al.
Publicado: (2011)

Immunotherapy and Immune Evasion in Prostate Cancer
por: Thakur, Archana, et al.
Publicado: (2013)

The Cellular and Molecular Immunotherapy in Prostate Cancer
por: Mukherjee, Anirban Goutam, et al.
Publicado: (2022)

Current Perspectives in Cancer Immunotherapy
por: Christofi, Theodoulakis, et al.
Publicado: (2019)

Epigenetic Perspective of Immunotherapy for Cancers
por: Keshari, Sunita, et al.
Publicado: (2023)

The Role of Sphingolipids in Cancer Immunotherapy
por: Giussani, Paola, et al.
Publicado: (2021)

Immunotherapy for Prostate Cancer: Where We Are Headed
por: Schepisi, Giuseppe, et al.
Publicado: (2017)

Emerging Immunotherapy Approaches for Treating Prostate Cancer
por: Meng, Lingbin, et al.
Publicado: (2023)

Comparative Prospective and Longitudinal Analysis on the Platelet-to-Lymphocyte, Neutrophil-to-Lymphocyte, and Albumin-to-Globulin Ratio in Patients with Non-Metastatic and Metastatic Prostate Cancer
por: Salciccia, Stefano, et al.
Publicado: (2022)

Immunotherapy – new perspective in lung cancer
por: Pinheiro, Fillipe Dantas, et al.
Publicado: (2020)

Perspectives on immunotherapy via oncolytic viruses
por: Reale, Alberto, et al.
Publicado: (2019)

Comparison of Different Invasive Devices for the Treatment of Urinary Incontinence after Radical Prostatectomy
por: Salciccia, Stefano, et al.
Publicado: (2022)

Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes
por: Salciccia, Stefano, et al.
Publicado: (2021)

Dendritic Cell-Based Immunotherapy for Prostate Cancer
por: Jähnisch, Hanka, et al.
Publicado: (2010)

From Bench to Bedside: Immunotherapy for Prostate Cancer
por: Tse, Brian Wan-Chi, et al.
Publicado: (2014)

Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives
por: Rehman, Laeeq ur, et al.
Publicado: (2023)

Immunotherapy for Prostate Cancer Enters Its Golden Age
por: Boikos, Sosipatros A., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_kfc272hg5nq7k9ira2ahkatgie